Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

Dow Jones

Oct 15

By Connor Hart

Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults.

The healthcare-products maker on Wednesday posted a profit of $1.64 billion, or 94 cents a share, roughly flat from a year ago.

Stripping out one-time items, adjusted earnings were $1.30 a share, in line with analyst expectations, according to FactSet.

Sales rose 6.9% to $11.37 billion, also in line with Wall Street models.

The company said growth in the quarter was led by adult nutrition, where sales increased 5.8%, led by its Ensure nutritional shakes and drinks.

For the year, Abbott narrowed its adjusted earnings outlook to $5.12 to $5.18 a share, compared with a prior view of $5.10 to $5.20 a share. It backed its organic sales growth forecast of 6% to 7% when including Covid-19 testing-related sales.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

October 15, 2025 07:47 ET (11:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575020789"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575020789\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575020789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-15 19:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575020789","market":"sg","top_or_hot":-1,"title":"Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults. \n</p>\n<p>\n  The healthcare-products maker on Wednesday posted a profit of $1.64 billion, or 94 cents a share, roughly flat from a year ago. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $1.30 a share, in line with analyst expectations, according to FactSet. \n</p>\n<p>\n  Sales rose 6.9% to $11.37 billion, also in line with Wall Street models. \n</p>\n<p>\n  The company said growth in the quarter was led by adult nutrition, where sales increased 5.8%, led by its Ensure nutritional shakes and drinks. \n</p>\n<p>\n  For the year, Abbott narrowed its adjusted earnings outlook to $5.12 to $5.18 a share, compared with a prior view of $5.10 to $5.20 a share. It backed its organic sales growth forecast of 6% to 7% when including Covid-19 testing-related sales. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 15, 2025 07:47 ET (11:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbott Labs Posts Higher 3Q Sales, Reaffirms Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-15 19:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults. \n</p>\n<p>\n  The healthcare-products maker on Wednesday posted a profit of $1.64 billion, or 94 cents a share, roughly flat from a year ago. \n</p>\n<p>\n  Stripping out one-time items, adjusted earnings were $1.30 a share, in line with analyst expectations, according to FactSet. \n</p>\n<p>\n  Sales rose 6.9% to $11.37 billion, also in line with Wall Street models. \n</p>\n<p>\n  The company said growth in the quarter was led by adult nutrition, where sales increased 5.8%, led by its Ensure nutritional shakes and drinks. \n</p>\n<p>\n  For the year, Abbott narrowed its adjusted earnings outlook to $5.12 to $5.18 a share, compared with a prior view of $5.10 to $5.20 a share. It backed its organic sales growth forecast of 6% to 7% when including Covid-19 testing-related sales. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 15, 2025 07:47 ET (11:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABT","symbol_name":"雅培","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2575020789","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575020789","pubTimestamp":1760528820,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults.The healthcare-products maker on Wednesday posted a profit of $1.64 billion, or 94 cents a share, roughly flat from a year ago.Stripping out one-time items, adjusted earnings were $1.30 a share, in line with analyst expectations, according to FactSet.Sales rose 6.9% to $11.37 billion, also in line with Wall Street models.The company said growth in the quarter was led by adult nutrition, where sales increased 5.8%, led by its Ensure nutritional shakes and drinks.For the year, Abbott narrowed its adjusted earnings outlook to $5.12 to $5.18 a share, compared with a prior view of $5.10 to $5.20 a share. It backed its organic sales growth forecast of 6% to 7% when including Covid-19 testing-related sales.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ABT":"雅培"},"translate_title":"雅培实验室第三季度销售额增长，重申前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":1.5},"content_text":"By Connor Hart \n\n\n \n\n\n  Abbott Laboratories backed its full-year outlook after posting higher sales in the third quarter, boosted by sales of its nutrition shakes and drinks for adults. \n\n\n  The healthcare-products maker on Wednesday posted a profit of $1.64 billion, or 94 cents a share, roughly flat from a year ago. \n\n\n  Stripping out one-time items, adjusted earnings were $1.30 a share, in line with analyst expectations, according to FactSet. \n\n\n  Sales rose 6.9% to $11.37 billion, also in line with Wall Street models. \n\n\n  The company said growth in the quarter was led by adult nutrition, where sales increased 5.8%, led by its Ensure nutritional shakes and drinks. \n\n\n  For the year, Abbott narrowed its adjusted earnings outlook to $5.12 to $5.18 a share, compared with a prior view of $5.10 to $5.20 a share. It backed its organic sales growth forecast of 6% to 7% when including Covid-19 testing-related sales. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 15, 2025 07:47 ET (11:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}